PTGS2 and neoplasm: •Synergistic Immuno-Metabolic Therapy: Releases CXB to suppress inflammation and enhance CTL infiltration, while Lipo blocks tumor fatty acid uptake in OTME, synergistically amplifying CTL activation via targeting the AA/COX-2/PGE2 axis to prevent recurrence.